BCAL Diagnostics (ASX:BDX) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

BCAL Diagnostics's Capital Expenditure for the six months ended in Dec. 2023 was A$-0.13 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-4.22 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

BCAL Diagnostics Capex-to-Operating-Income Historical Data

The historical data trend for BCAL Diagnostics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Capex-to-Operating-Income Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Jun24

Capex-to-Operating-Income

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capex-to-Operating-Income	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of BCAL Diagnostics's Capex-to-Operating-Income

For the Diagnostics & Research subindustry, BCAL Diagnostics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Capex-to-Operating-Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Capex-to-Operating-Income falls into.

BCAL Diagnostics Capex-to-Operating-Income Calculation

BCAL Diagnostics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1.151)	/	-9.398
	=	N/A

BCAL Diagnostics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.129)	/	-4.215
	=	N/A

BCAL Diagnostics (ASX:BDX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

BCAL Diagnostics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.